Stock Track | HUTCHMED Plummets 7.49% as FY25 Revenue Guidance Update Disappoints Investors

Stock Track

Aug 08

HUTCHMED (China) Ltd, trading under the stock code 00013, saw its shares plummet by 7.49% in Friday's pre-market trading session. The significant drop comes on the heels of the company's announcement regarding its fiscal year 2025 guidance for oncology and immunology consolidated revenue.

In a statement released late Thursday, HUTCHMED updated its FY25 guidance for oncology/immunology consolidated revenue to a range of $270 million to $350 million. While the company did not provide the previous guidance figures in the announcement, the market reaction suggests that this update may be lower than investors' expectations.

The sharp decline in HUTCHMED's stock price reflects investors' concerns about the company's future revenue prospects in its key oncology and immunology segments. As a biopharmaceutical company focused on developing novel therapies in these areas, any adjustment to revenue projections can significantly impact investor sentiment. Analysts and shareholders will likely be closely monitoring the company's upcoming communications for further clarification on the factors influencing this guidance update and its potential implications for HUTCHMED's long-term growth strategy.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1199384537"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1199384537\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1199384537?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-08 09:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199384537","market":"us","top_or_hot":-1,"title":"Stock Track | HUTCHMED Plummets 7.49% as FY25 Revenue Guidance Update Disappoints Investors","media":"Stock Track","content":"<p>HUTCHMED (China) Ltd, trading under the stock code 00013, saw its shares plummet by 7.49% in Friday's pre-market trading session. The significant drop comes on the heels of the company's announcement regarding its fiscal year 2025 guidance for oncology and immunology consolidated revenue.</p>\n\n<p>In a statement released late Thursday, HUTCHMED updated its FY25 guidance for oncology/immunology consolidated revenue to a range of $270 million to $350 million. While the company did not provide the previous guidance figures in the announcement, the market reaction suggests that this update may be lower than investors' expectations.</p>\n\n<p>The sharp decline in HUTCHMED's stock price reflects investors' concerns about the company's future revenue prospects in its key oncology and immunology segments. As a biopharmaceutical company focused on developing novel therapies in these areas, any adjustment to revenue projections can significantly impact investor sentiment. Analysts and shareholders will likely be closely monitoring the company's upcoming communications for further clarification on the factors influencing this guidance update and its potential implications for HUTCHMED's long-term growth strategy.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | HUTCHMED Plummets 7.49% as FY25 Revenue Guidance Update Disappoints Investors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | HUTCHMED Plummets 7.49% as FY25 Revenue Guidance Update Disappoints Investors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-08 09:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HUTCHMED (China) Ltd, trading under the stock code 00013, saw its shares plummet by 7.49% in Friday's pre-market trading session. The significant drop comes on the heels of the company's announcement regarding its fiscal year 2025 guidance for oncology and immunology consolidated revenue.</p>\n\n<p>In a statement released late Thursday, HUTCHMED updated its FY25 guidance for oncology/immunology consolidated revenue to a range of $270 million to $350 million. While the company did not provide the previous guidance figures in the announcement, the market reaction suggests that this update may be lower than investors' expectations.</p>\n\n<p>The sharp decline in HUTCHMED's stock price reflects investors' concerns about the company's future revenue prospects in its key oncology and immunology segments. As a biopharmaceutical company focused on developing novel therapies in these areas, any adjustment to revenue projections can significantly impact investor sentiment. Analysts and shareholders will likely be closely monitoring the company's upcoming communications for further clarification on the factors influencing this guidance update and its potential implications for HUTCHMED's long-term growth strategy.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00013","symbol_name":"和黄医药","start_time":0,"source_url":"","article_id":"1199384537","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199384537","pubTimestamp":1754616658,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"HUTCHMED (China) Ltd, trading under the stock code 00013, saw its shares plummet by 7.49% in Friday's pre-market trading session. The significant drop comes on the heels of the company's announcement...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00013":"和黄医药"},"translate_title":"个股追踪|和黄医药暴跌7.49%因25财年营收指引更新令投资者失望","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":1},"content_text":"HUTCHMED (China) Ltd, trading under the stock code 00013, saw its shares plummet by 7.49% in Friday's pre-market trading session. The significant drop comes on the heels of the company's announcement regarding its fiscal year 2025 guidance for oncology and immunology consolidated revenue.\nIn a statement released late Thursday, HUTCHMED updated its FY25 guidance for oncology/immunology consolidated revenue to a range of $270 million to $350 million. While the company did not provide the previous guidance figures in the announcement, the market reaction suggests that this update may be lower than investors' expectations.\nThe sharp decline in HUTCHMED's stock price reflects investors' concerns about the company's future revenue prospects in its key oncology and immunology segments. As a biopharmaceutical company focused on developing novel therapies in these areas, any adjustment to revenue projections can significantly impact investor sentiment. Analysts and shareholders will likely be closely monitoring the company's upcoming communications for further clarification on the factors influencing this guidance update and its potential implications for HUTCHMED's long-term growth strategy.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}